Table 2.

Estimated effects (β) and 95% confidence intervals of brain bromine levels on Alzheimer’s disease (AD) neuropathology in a cross-sectional analysis among 215 deceased brains^*

	Bromine levels by tertile			p for trend
	1	2	3
Global AD pathology
β	Referent	0.37	0.38	0.11
95% CI		(−0.03, 0.76)	(−0.01, 0.78)
Neuritic plaque density (CERAD)
β	Referent	0.38	0.50	0.02
95% CI		(0.01, 0.74)	(0.13, 0.86)
Neurofibrillary tangle severity (Braak stage)
β	Referent	0.56	0.55	0.02
95% CI		(0.18, 0.94)	(0.17, 0.93)
AD diagnostic score (NIA Regan)
β	Referent	0.24	0.34	0.01
95% CI		(0.01, 0.47)	(0.11, 0.57)

^∗Linear regression models adjusted for age at death, sex, education, and APOE ε4.